Evidence map›Paper›PMID 35042842›Full record

ArticleCell death & disease2022

MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma.

Dechen Fu, Luke Pfannenstiel, Abeba Demelash, Yee Peng Phoon, Cameron Mayell, Claudia Cabrera, Caini Liu, Junjie Zhao, Josephine Dermawan, Deepa Patil and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. MCL1 may not mediate chemoresistance.bioRxiv : the preprint server for biology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Dechen FuDepartment of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Luke PfannenstielDepartment of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Abeba DemelashDepartment of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Yee Peng PhoonDepartment of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. phoony@ccf.org.
Cameron MayellCleveland State University, Cleveland, OH, USA.ORCID http://orcid.org/0000-0003-2416-626X
Claudia CabreraCase Western Reserve University, Cleveland, OH, USA.
Caini LiuDepartment of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Junjie ZhaoDepartment of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Josephine DermawanPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Deepa PatilDigestive Health Research Institute, Case Western Reserve University, Cleveland, OH, USA.
Jennifer DeVecchioCenter for Cancer Stem cell Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Matthew KaladyCenter for Cancer Stem cell Research, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Andrew J SouersOncology-Discovery, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064, USA.
Darren C PhillipsOncology-Discovery, AbbVie Inc, 1 North Waukegan Road, North Chicago, IL, 60064, USA.
Xiaoxia LiDepartment of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
Brian GastmanDepartment of Inflammation and immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. gastmab@ccf.org.ORCID http://orcid.org/0000-0003-2691-3409
Cleveland Clinic Lerner College of Medicine · USAbbVie (United States) · USCase Western Reserve University · USCleveland Clinic · USCleveland State University · US

Funding

Mechanisms of nuclear Mcl-1 mediated chemoresistanceR01CA244958 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI MELENHORST, JAN J · 2021 to 2025
$1.8M
NCI NIH HHS R01 CA244958
6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer. Myeloid Cell Leukemia 1 (MCL1), a pro-survival member of the Bcl-2 protein family is associated with chemo-resistance in CRC. The ability of MCL1 to inhibit apoptosis by binding to the BH3 domains of pro-apoptotic Bcl-2 family members is a well-studied means by which this protein confers resistance to multiple anti-cancer therapies. We found that specific DNA damaging chemotherapies promote nuclear MCL1 translocation in CRC models. In p53

Indexed as

Colorectal NeoplasmsDrug Resistance, NeoplasmMyeloid Cell Leukemia Sequence 1 ProteinApoptosisCell Line, TumorHumansProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53MCL1 protein, humanMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2Tumor Suppressor Protein p53

Identifiers

PMID35042842
PMCPMC8766550
OpenAlexW4206594822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.